BSE: 500126
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Outperformed both Sector by 26.05% and Sensex by 13.21%
MARKET CAP (Mid Cap Stock)Rs 8,145 Cr
PE (TTM) 35.01
PE Ratio35.01
Price to Book Value11.10
EV to EBIT26.00
EV to EBITDA23.67
EV to Capital Employed23.03
EV to Sales6.62
PEG Ratio0.63
Dividend Yield1.99%
ROCE (Latest)88.57%
ROE (Latest)31.70%
NameDec 22Sep 22
Promoters (Change:0.00) 51.82%51.82%
FIIs (Change:0.28) 6.33%6.05%
Mutual Funds (Change:0.38) 7.28%6.9%
Insurance Companies (Change:-0.55) 5.11%5.66%
Other DIIs (Change:-0.01) 0.05%0.06%
Non Institution (Change:-0.09) 29.42%29.51%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000


Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %


Frequently Asked Questions

What is the Share price of MERCK LIMITED (MERCK)?

MERCK LIMITED (MERCK) share price as of March 20, 2023, on NSE is Rs 4,916.45 (NSE) and Rs 4,910.00 (BSE) on BSE.

Can I buy MERCK LIMITED (MERCK) shares?

Yes, You can buy MERCK LIMITED (MERCK) shares by opening a Demat account with Angel One.

How do I buy MERCK LIMITED (MERCK) from Angel One?

MERCK LIMITED (MERCK) share can be brought through the following modes:
  1. Direct investment: You can buy MERCK LIMITED (MERCK) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to MERCK LIMITED (MERCK) shares.

In which sector do MERCK LIMITED (MERCK) belong?

MERCK LIMITED (MERCK) belongs to Pharma.


Today's live share price for MERCK LIMITED is NSE: ₹ 4,916.45, BSE: ₹ 4,910.00 with a current market capitalization of .

Merck Ltd is an Indian-based company. The company is the supplier of Pharmaceutical Chemicals, Formulated Chemical Products, Chemicals, Industrial Chemicals, Chemicals, Pharmaceutical Industry, and Chemical Products. They are engaged in the production and sale of pharmaceuticals and chemicals in India. The company offer prescription drugs, biotechnology products, and consumer health products, including over-the-counter products. They also offer products for the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases, and other conditions with unmet medical needs. The company operates in two business divisions, namely Pharmaceuticals and Chemicals. The Pharmaceuticals business comprises of Ethicals used in the treatment of Cardiovascular and Metabolic diseases & Vitamin-based formulations and Consumer Health Care Products. The Chemicals business comprises of Bulk Drugs and Pigments. Segment revenue relating to the Chemicals business consists of bulk drugs, pigments and active pharmaceutical ingredients. Merck Ltd was incorporated in the year 1967 as E Merck (India) Ltd. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities. The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. The company started their operations as a manufacturer of pharmaceutical specialties and over the years, they have diversified their product range to include basic drugs, fine and industrial chemicals, and diagnostics. In the year 1981, the company became a public limited company they were the first in the Merck group. In December 2000, the company acquired the Livogen brand from Glaxo India for a consideration of Rs 8 crore. They entered into a co-marketing tie-up with the domestic Pharma company Kopran for a new anti-inflammatory drug Rofecoxib, in the country. They launched new drug under the brand name of 'Acrobat', while Kopran launched the product under the brand name of 'Ziflam'. In the year 2002, the company launched Anti-diabetic molecule, namely 'Glimepiride' in the market. They changed their name from E Merck (India) Ltd to Merck Ltd with effect from March 27, 2002 in order to create one strong international Merck brand and to develop a uniform international image. In the year 2004, the company sold their Taloja undertaking to Biochem Pharmaceutical Industries Ltd for a consideration of Rs 100 million. In addition, the Pharma section of the company started a new unit, namely Consumer Health Care to market medicines for common ailments. In the same year, the company formed a Public Charitable Trust known as 'Merck India Charitable Trust' with the main object of rendering financial assistance to children from the poorer section of society, to pursue primary and secondary education. In the year 2005, the company increased the production capacity of Bulk Drugs by 18 tonnes to 318 tonnes. They launched a new product, namely Pedimune, which is a formulation to improve the immunity level of Children. In the year 2006, the company expanded the production capacity of Bulk Drugs by 33 tonnes to 351 tonnes. In April 2006, the Life Science and Analytics (excluding Bulk Drugs) Business (LS&A business) of the Division was sold to Merck Specialities Pvt Ltd. All the assets and rights on the manufacturing and distribution facilities were transferred to Merck Specialities Pvt Ltd. In the year 2007, the company increased the production capacity of Injection/ Nasal Drops by 24 kilolitres to 427 kiloliters. The Pharmaceuticals segments launched Olmighty Tablets, Evion Forte Tablets, Polybion Complete Syrup, Met Neurobion Injection, Livogen CZ Tablets and Nasivion Care Drops. In the year 2008, the company expanded the production capacity of Bulk Drugs by 128 tonnes to 479 tonnes, Injection/ Nasal Drops by 13 kiloliters to 440 kiloliters and Tablets/ Capsules by 40 million Nos to 400 million Nos. In addition, they commissioned the project for the substantial expansion of the production capacity of their patented molecule, Oxynex ST. This plant is a 100% export-oriented unit and having a capacity to produce around 150 tonnes per year.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers